Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study
- PMID: 33737406
- DOI: 10.1183/13993003.03823-2020
Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study
Abstract
Aim: The impact of blood eosinophil counts on the development of chronic obstructive lung disease (COPD) is unknown. We investigated whether a higher blood eosinophil count was associated with the risk of developing obstructive lung disease (OLD) in a large cohort of men and women free from lung disease at baseline.
Methods: This was a cohort study of 359 456 Korean adults without a history of asthma and without OLD at baseline who participated in health screening examinations including spirometry. OLD was defined as pre-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0.7 and FEV1 <80% predicted.
Results: After a median (interquartile range) follow-up of 5.6 (2.9-9.2) years, 5008 participants developed incident OLD (incidence rate 2.1 (95% CI 2.1-2.2) per 1000 person-years). In the fully adjusted model, the hazard ratios for incident OLD comparing eosinophil counts of 100- <200, 200- <300, 300- <500 and ≥500 versus <100 cells·μL-1 were 1.07 (95% CI 1.00-1.15), 1.30 (95% CI 1.20-1.42), 1.46 (95% CI 1.33-1.60) and 1.72 (95% CI 1.51-1.95), respectively (ptrend<0.001). These associations were consistent in clinically relevant subgroups, including never-, ex- and current smokers.
Conclusion: In this large longitudinal cohort study, blood eosinophil counts were positively associated with the risk of developing of OLD. Our findings indicate a potential role of the eosinophil count as an independent risk factor for developing COPD.
Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org.
Conflict of interest statement
Conflict of interest: H.Y. Park has nothing to disclose. Conflict of interest: Y. Chang has nothing to disclose. Conflict of interest: D. Kang has nothing to disclose. Conflict of interest: Y.S. Hong has nothing to disclose. Conflict of interest: D. Zhao has nothing to disclose. Conflict of interest: J. Ahn has nothing to disclose. Conflict of interest: S.H. Shin has nothing to disclose. Conflict of interest: D. Singh reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Theravance and Verona, outside the submitted work. Conflict of interest: E. Guallar has nothing to disclose. Conflict of interest: J. Cho has nothing to disclose. Conflict of interest: S. Ryu has nothing to disclose.
Comment in
-
A new piece in the puzzle: the eosinophil and the development of COPD.Eur Respir J. 2021 Oct 7;58(4):2101105. doi: 10.1183/13993003.01105-2021. Print 2021 Oct. Eur Respir J. 2021. PMID: 34620680 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical